Sociedad Americana de Hirudoterapia

Androgenic Alopecia

Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.

Tier C — InvestigationalInvestigacionalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Resumen para el Paciente

¿Está esto autorizado por FDA para este uso?
Not FDA-cleared for androgenic alopecia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
¿Qué evidencia existe?
Tier C (investigational). Two small single-arm case series report modest trichoscopic hair-density increases (about 3 to 7 percent) after 6 monthly sessions; there are no randomized controlled trials. Evidence-based options with FDA approval and decades of data are topical minoxidil 2 percent / 5 percent (men and women), oral finasteride 1 mg (men), oral dutasteride (off-label, robust evidence), low-level laser therapy devices, and platelet-rich plasma injections. Hair transplantation is the definitive option for advanced loss.
Riesgos principales
  • Bleeding from bite sites on the scalp for 6 to 24 hours after detachment
  • Bruising and tenderness over the scalp for 5 to 10 days
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Temporary telogen effluvium (stress-related shedding) at the application sites
  • Cosmetic visible small scars at bite sites
  • Wasted time and money if used INSTEAD OF proven minoxidil, finasteride, or transplantation
Quién no debería considerar esto
  • Patients with active scalp infection, seborrheic dermatitis, or psoriasis at proposed sites
  • Patients within 3 months of a hair transplant procedure
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients with undiagnosed hair loss (need to rule out telogen effluvium, alopecia areata, scarring alopecia)
  • Patients who have not tried evidence-based first-line therapy (minoxidil for both sexes; finasteride for men)
  • Patients with active scalp malignancy or atypical nevi at proposed sites
Qué preguntar a su clínico
  • Has my hair loss been confirmed as androgenic alopecia (Norwood scale for men, Ludwig for women)?
  • Have I tried topical minoxidil (5 percent) consistently for at least 6 months?
  • Am I a candidate for oral finasteride (men) or dutasteride / spironolactone (women off-label)?
  • Have I considered low-level laser therapy, PRP, or hair transplantation?
  • What is the realistic effect size with leech therapy versus proven options?
  • What is the practitioner's experience and Aeromonas-prevention plan?
  • What is the cost compared to evidence-based therapy?
Cuándo buscar atención urgente
  • Spreading redness, warmth, pus, or red streaks on the scalp (cellulitis)
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Fever above 38.0 C / 100.4 F or chills
  • Sudden patchy hair loss with smooth bald patches (alopecia areata — needs dermatology evaluation)
  • Scalp scarring, redness, or pain with hair loss (scarring alopecia — needs urgent dermatology evaluation)
  • Hives, throat tightness, or breathing difficulty

Qué NO significa esto

  • This is not FDA-cleared for androgenic alopecia.
  • Small uncontrolled series with modest density changes do NOT establish efficacy versus minoxidil or finasteride.
  • Mechanism rationale (microcirculatory improvement, growth-factor stimulation) does NOT establish clinical efficacy.
  • Leech therapy is not a substitute for proven topical minoxidil, oral finasteride / dutasteride, PRP, or hair transplantation.
  • Hair loss progression cannot be halted by leech therapy in the way that 5-alpha-reductase inhibitors have been shown to do.

Clinical Profile

Category
dermatological
ICD-10
L64.0, L64.8, L64.9
Safety tier
low

Evidence Summary

No controlled trial or quantified case series of leech therapy for androgenic alopecia has been published; use is investigational and mechanistic only. The speculative rationale is local microcirculatory improvement plus growth-factor stimulation of the scalp, but no clinical evidence supports an increase in hair density or terminal hair count. It is too preliminary to recommend over established treatments (minoxidil, finasteride, low-level laser therapy, PRP). Although it is sometimes combined with PRP in integrative protocols, no controlled comparison exists. ASH position: investigational only, with no demonstrated benefit.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Khan MA et al. (2020), n=24

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Active scalp infection or seborrheic dermatitis
  • Recent (<3 months) hair transplant

Related Conditions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.

Androgenic Alopecia — Hirudotherapy Evidence | ASH